You are here: All Products  > Ascentage-Innovent NDA Accepted for Priority Review as Chronic Myeloid Leukemia Therapy

Ascentage-Innovent NDA Accepted for Priority Review as Chronic Myeloid Leukemia Therapy

Price: $5.00
Available

Get instant access to this article for unlimited viewing and/or downloading for seven days.


Back to products